Phase II trials: SVR rate and 95% CI with DAA in HCVG1 naives. Blue, Triple combo with Protease Inhibitors (PI) + Pegylated interferon (P) + Ribavirin ( R ). Purple, Triple combo with NS5aPol inhbitors + PR. Yellow, QUAD two antivirals acting on viral protease and polymerase with pegylated interferon + ribavirin. Green, Interferon free combos. They are NOT HEAD TO HEAD STUDIES.
Puoti et al. BMC Infectious Diseases 2012 12(Suppl 2):S7 doi:10.1186/1471-2334-12-S2-S7